Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted Human Immunodeficiency Virus Type 1 Drug Resistance in a Large US Clinic Population

• Published in: Clinical infectious diseases 2019-01, Vol.68 (2), p.213-221
• Main Authors: Rhee, Soo-Yon, Clutter, Dana, Fessel, W Jeffrey, Klein, Daniel, Slome, Sally, Pinsky, Benjamin A, Marcus, Julia L, Hurley, Leo, Silverberg, Michael J, Kosakovsky Pond, Sergei L, Shafer, Robert W
• Format: Article
• Language: English
• Subjects: Adult; and Commentaries; Anti-HIV Agents - pharmacology; Drug Resistance, Multiple, Viral; Female; HIV Infections - drug therapy; HIV Infections - epidemiology; HIV Infections - virology; HIV-1 - drug effects; HIV-1 - genetics; Humans; Male; Molecular Epidemiology; Mutation; Phylogeny; Prevalence; Selection, Genetic; Time Factors; United States - epidemiology
• ISSN: 1058-4838; 1537-6591
• DOI: 10.1093/cid/ciy453

Between 2003 and 2016, transmitted HIV-1 drug resistance has increased in a large California clinic population. However, the most commonly transmitted drug-resistance mutations reduce susceptibility primarily to drugs that are no longer frequently used. Abstract Background There are few large studies of transmitted drug resistance (TDR) prevalence and the drug resistance mutations (DRMs) responsible for TDR in the United States. Methods Human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) and protease sequences were obtained from 4253 antiretroviral therapy (ART)-naive individuals in a California clinic population from 2003 to 2016. Phylogenetic analyses were performed to study linkages between TDR strains and selection pressure on TDR-associated DRMs. Results From 2003 to 2016, there was a significant increase in overall (odds ratio [OR], 1.05 per year [95% confidence interval {CI}, 1.03-1.08]; P < .001) and nonnucleoside RT inhibitor (NNRTI)-associated TDR (OR, 1.11 per year [95% CI, 1.08-1.15]; P < .001). Between 2012 and 2016, TDR rates to any drug class ranged from 15.7% to 19.2%, and class-specific rates ranged from 10.0% to 12.8% for NNRTIs, 4.1% to 8.1% for nucleoside RT inhibitors (NRTIs), and 3.6% to 5.2% for protease inhibitors. The thymidine analogue mutations, M184V/I and the tenofovir-associated DRMs K65R and K70E/Q/G/N/T accounted for 82.9%, 7.3%, and 1.4% of NRTI-associated TDR, respectively. Thirty-seven percent of TDR strains clustered with other TDR strains sharing the same DRMs. Conclusions Although TDR has increased significantly in this large cohort, many TDR strains are unlikely to influence the activity of currently preferred first-line ART regimens. The high proportion of DRMs associated with infrequently used regimens combined with the clustering of TDR strains suggest that some TDR strains are being transmitted between ART-naive individuals.